277 related articles for article (PubMed ID: 29029545)
1. The role of toll-like receptor 4 in tumor microenvironment.
Li J; Yang F; Wei F; Ren X
Oncotarget; 2017 Sep; 8(39):66656-66667. PubMed ID: 29029545
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 4 signaling promotes tumor growth.
Lee CH; Wu CL; Shiau AL
J Immunother; 2010 Jan; 33(1):73-82. PubMed ID: 19952954
[TBL] [Abstract][Full Text] [Related]
3. Interactions between tumor-derived proteins and Toll-like receptors.
Jang GY; Lee JW; Kim YS; Lee SE; Han HD; Hong KJ; Kang TH; Park YM
Exp Mol Med; 2020 Dec; 52(12):1926-1935. PubMed ID: 33299138
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 4-induced inflammatory responses contribute to the tumor-associated macrophages formation and infiltration in patients with diffuse large B-cell lymphoma.
Wang X; Li X; Zhang X; Zang L; Yang H; Zhao W; Zhao H; Li Q; Xia B; Yu Y; Wang Y; Zhao Z; Zhang Y
Ann Diagn Pathol; 2015 Aug; 19(4):232-8. PubMed ID: 26071054
[TBL] [Abstract][Full Text] [Related]
5. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
7. The Role of Toll-Like Receptor in Inflammation and Tumor Immunity.
Cen X; Liu S; Cheng K
Front Pharmacol; 2018; 9():878. PubMed ID: 30127747
[TBL] [Abstract][Full Text] [Related]
8. Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment.
Deguchi A; Tomita T; Ohto U; Takemura K; Kitao A; Akashi-Takamura S; Miyake K; Maru Y
Oncogene; 2016 Mar; 35(11):1445-56. PubMed ID: 26165843
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
10. The role of toll-like receptor 4 (TLR4) in cancer progression: A possible therapeutic target?
Kashani B; Zandi Z; Pourbagheri-Sigaroodi A; Bashash D; Ghaffari SH
J Cell Physiol; 2021 Jun; 236(6):4121-4137. PubMed ID: 33230811
[TBL] [Abstract][Full Text] [Related]
11. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
Cui J; Chen Y; Wang HY; Wang RF
Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
[TBL] [Abstract][Full Text] [Related]
13. Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling.
Maruyama A; Shime H; Takeda Y; Azuma M; Matsumoto M; Seya T
Biochem Biophys Res Commun; 2015 Feb; 457(3):445-50. PubMed ID: 25596131
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment is multifaceted.
Sautès-Fridman C; Cherfils-Vicini J; Damotte D; Fisson S; Fridman WH; Cremer I; Dieu-Nosjean MC
Cancer Metastasis Rev; 2011 Mar; 30(1):13-25. PubMed ID: 21271351
[TBL] [Abstract][Full Text] [Related]
15. Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer.
Mehmeti M; Allaoui R; Bergenfelz C; Saal LH; Ethier SP; Johansson ME; Jirström K; Leandersson K
Breast Cancer Res; 2015 Sep; 17(1):130. PubMed ID: 26392082
[TBL] [Abstract][Full Text] [Related]
16. Innate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity.
Cordiglieri C; Marolda R; Franzi S; Cappelletti C; Giardina C; Motta T; Baggi F; Bernasconi P; Mantegazza R; Cavalcante P
J Autoimmun; 2014 Aug; 52():74-89. PubMed ID: 24397961
[TBL] [Abstract][Full Text] [Related]
17. Staphylococcal enterotoxins condition cells of the innate immune system for Toll-like receptor 4 stimulation.
Rossi RJ; Muralimohan G; Maxwell JR; Vella AT
Int Immunol; 2004 Dec; 16(12):1751-60. PubMed ID: 15504761
[TBL] [Abstract][Full Text] [Related]
18. Topographical changes in extracellular matrix: Activation of TLR4 signaling and solid tumor progression.
Kelsh RM; McKeown-Longo PJ
Trends Cancer Res; 2013 Jan; 9():1-13. PubMed ID: 24634571
[TBL] [Abstract][Full Text] [Related]
19. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease.
Pasterkamp G; Van Keulen JK; De Kleijn DP
Eur J Clin Invest; 2004 May; 34(5):328-34. PubMed ID: 15147329
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 4 mediates the antitumor host response induced by a 55-kilodalton protein isolated from Aeginetia indica L., a parasitic plant.
Okamoto M; Oh-E G; Oshikawa T; Furuichi S; Tano T; Ahmed SU; Akashi S; Miyake K; Takeuchi O; Akira S; Himeno K; Sato M; Ohkubo S
Clin Diagn Lab Immunol; 2004 May; 11(3):483-95. PubMed ID: 15138173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
